Procyrion Inc. of Houston has been awarded the grand prize of $20,000 in the 2015 "Create the Future" Design Contest for the first catheter-deployed heart pump intended for long-term treatment of chronic heart failure.

Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the study presented by a prominent heart failure (HF) specialist during a major cardiology congress in the United States show that autonomic regulation therapy (ART) in patients with moderate to severe chronic HF and impaired heart function is well-tolerated, safe, improves the heart's ability to pump blood, and reduces the frequency and severity of symptoms associated with chronic HF.

Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and European investigational device exemption (IDE) clinical trial of the Tack Endovascular System.

Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries. The approval makes it the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.

October 1, 2015 — Infinitt North America will feature the Infinitt Healthcare Platform (IHP) at RSNA 2015. This ...

A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and restore their metabolism after transplantation, improving cardiac function after simulated heart attacks, according to results of a new study.